CBUS vs. MBII, LFVN, NAII, BIOX, AVD, CGA, EVGN, SNES, NITO, and SVFD
Should you be buying Cibus stock or one of its competitors? The main competitors of Cibus include Marrone Bio Innovations (MBII), LifeVantage (LFVN), Natural Alternatives International (NAII), Bioceres Crop Solutions (BIOX), American Vanguard (AVD), China Green Agriculture (CGA), Evogene (EVGN), SenesTech (SNES), N2OFF (NITO), and Save Foods (SVFD).
Marrone Bio Innovations (NASDAQ:MBII) and Cibus (NASDAQ:CBUS) are both small-cap basic materials companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends, valuation and community ranking.
In the previous week, Cibus had 7 more articles in the media than Marrone Bio Innovations. MarketBeat recorded 7 mentions for Cibus and 0 mentions for Marrone Bio Innovations. Marrone Bio Innovations' average media sentiment score of 0.00 beat Cibus' score of -0.38 indicating that Cibus is being referred to more favorably in the news media.
Marrone Bio Innovations has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, Cibus has a beta of 1.92, suggesting that its stock price is 92% more volatile than the S&P 500.
68.4% of Marrone Bio Innovations shares are held by institutional investors. Comparatively, 33.8% of Cibus shares are held by institutional investors. 5.0% of Marrone Bio Innovations shares are held by company insiders. Comparatively, 49.4% of Cibus shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Cibus has a consensus price target of $25.00, suggesting a potential upside of 130.63%. Given Marrone Bio Innovations' higher probable upside, analysts clearly believe Cibus is more favorable than Marrone Bio Innovations.
Marrone Bio Innovations received 229 more outperform votes than Cibus when rated by MarketBeat users. However, 100.00% of users gave Cibus an outperform vote while only 49.68% of users gave Marrone Bio Innovations an outperform vote.
Marrone Bio Innovations has higher revenue and earnings than Cibus. Marrone Bio Innovations is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.
Marrone Bio Innovations has a net margin of -47.07% compared to Marrone Bio Innovations' net margin of -12,313.28%. Marrone Bio Innovations' return on equity of -23.33% beat Cibus' return on equity.
Summary
Cibus beats Marrone Bio Innovations on 11 of the 17 factors compared between the two stocks.
Get Cibus News Delivered to You Automatically
Sign up to receive the latest news and ratings for CBUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CBUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
